SEARCH

SEARCH BY CITATION

Additional supporting information can be found in the online version of this article.

FilenameFormatSizeDescription
ANA_22473_sm_suppfig1.tif19092KSupporting Figure 1 Indomethacin decreases both IBA-1 and GFAP florescent intensity. Panel A shows there was an increase in IBA-1 florescent intensity in the H/I Veh treated SVZ when compared to Controls (*, p < 0.05) and H/I Indomethacin treated (**, p < 0.05). However, there was more IBA-1 florescent intensity in the Indomethacin treated animals compared to Controls (+ p < 0.05). Panel B shows IBA-1 staining (red) and IL-6 staining (green) of the striatum and SVZ at 72 hours of recovery. Virtually all of the IL-6+ cells were IBA-1 positive. Panel C depicts an increase in GFAP florescent intensity in the H/I Veh treated SVZ when compared to Controls (*, p < 0.05) and H/I Indomethacin treated (**, p < 0.05). However, there was more GFAP florescent intensity in the Indomethacin treated animals compared to Controls (+ p < 0.05). Panel D shows the change in IL-6 mRNA expression in cultured astrocytes, microglia or mixed brain cells exposed to in vitro hypoxia (2% O2) and glucopenia (3 mM glucose). There is a significant increase in IL-6 mRNA expression in the microglia and mixed brain cells compared to controls.
ANA_22473_sm_suppfig2.tif21906KSupporting Figure 2 Indomethacin does not provide neuroprotection from Hypoxia/Ischemia. Panel A shows Control Vehicle brain, Panel B shows Control Indo brain, Panel C shows HI Vehicle, and Panel D shows HI Indomethacin. Panel E shows that there is a significant decrease in the area of the cortex of both HI Vehicle (*, p < 0.05) and HI Indomethacin treated (**, p < 0.05) compared to Control Vehicle. There is no significant difference between HI Vehicle and HI Indo.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.